With the crucial capability of directly killing tumor cells, tumor-infiltrating CD8+ T cells have been suggested to be effectively activated by anti-PD-1 blockade, and consequently dominate immunotherapy mechanism in NSCLC [15]. This evidence concerns the gene CD8A and neoplasm.